A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Trial details
- Registry ID
- NCT06218290
- Phase
- Phase 2
The FDA issued a complete response letter for Oxylanthanum Carbonate (OLC) on 29 Jun 2026.
Drug identity checked against registry records
Also recorded as OLC
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on DialysisNCT06218290 | UNCY | Phase 2 | Completed | 2024-05-29Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-06-29Day | Oxylanthanum CarbonateUnicycive Therapeutics, Inc · UNCY | FDA complete response letterComplete response letter | Not specified | Open original sourceRead source excerpt{"application_number": ["NDA 218607"], "letter_date": "06/29/2026", "letter_type": "COMPLETE RESPONSE", "company_name": "Unicycive Therapeutics Inc.", "file_name": "CRL_NDA218607_20260629.pdf"} First seen: 26 Sep 2026 · Evidence last checked: 26 Sep 2026 |